Methylphenidate extended-release oral suspension - Pfizer

Drug Profile

Methylphenidate extended-release oral suspension - Pfizer

Alternative Names: NWP 06; Quillivant XR

Latest Information Update: 15 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NextWave Pharmaceuticals
  • Developer Pfizer
  • Class Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 14 Jan 2013 Launched for Attention-deficit hyperactivity disorder in USA (PO)
  • 28 Nov 2012 NextWave Pharmaceuticals has been acquired by Pfizer
  • 01 Oct 2012 Registered for Attention-deficit hyperactivity disorder in USA (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top